Market Update (NYSE:JNJ): Johnson & Johnson Medical Devices & Diagnostics Businesses Expanding Market Leadership with Innovative Products and Customer-Focused Solutions

Johnson & Johnson (NYSE:JNJ) [PR Newswire] – NEW BRUNSWICK, N.J., May 22, 2014 /PRNewswire/ — At a meeting today with members of the investment community, senior leaders from the Medical Devices and Diagnostics (MD&D) segment of Johnson & Johnson (JNJ) will outline plans to improve patient outcomes and expand their market leadership through innovative products, new business models and a significant focus on fast-growing emerging markets. Johnson & Johnson’s MD&D segment is the world’s largest medical devices and diagnostics business, with $28.5 billion in total sales for 2013, driven by ten $1 billion-plus platforms that hold the number one or number two positions in their respective categories. This meaningful innovation is intended to help health care systems, governments and providers improve clinical outcomes, increase patient satisfaction and contain costs; “Our businesses are uniquely positioned to continue helping patients while also leading the industry by capitalizing on our breadth, depth and scale,” said Dominic J. Caruso, Vice President, Finance and Chief Financial Officer for Johnson & Johnson.
Read more on this.

Johnson & Johnson (JNJ), with a current value of $284.64B, began trading this morning at $100.58.
 
Today’s price range has been between $100.08 and $100.63 per share with its 52-week range being $82.12 to $101.98.
 
Priced at 17.20x this year’s forecasted earnings, JNJ shares are relatively expensive compared to the industry’s -3.26x forward p/e ratio.
 
And for dividend hunters, the company pays shareholders $2.80 per share annually in dividends, yielding 2.80%.
 
In a review of the consensus earnings estimate this quarter, 16 sell-side analysts are looking at $1.54 per share, which would be $0.06 better than the year-ago quarter and a $0.03 sequential increase. What we find to be interesting is that the full-year EPS estimate of $5.88 is a $0.36 better when compared to the previous year’s annual results.
 
The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $18.79 Billion. If realized, that would be a 5.09% increase over the year-ago quarter.
 
Recently, Barclays downgraded JNJ from Overweight to Equal Weight (Jan 10, 2014). Previously, RBC Capital Mkts upgraded JNJ from Sector Perform to Outperform.
 
Investors should keep in mind is that the average price target is $104.84, which is 4.24% above where the stock opened this morning.
 
Summary (NYSE:JNJ) :  Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women’s health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON’S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDÔME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; blood glucose monitoring and insulin delivery products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
 
Tag Helper ~ Stock Code: JNJ | Common Company name: Johnson & Johnson | Full Company name: Johnson & Johnson (NYSE:JNJ) .

NYSE, NASDAQ, Market Data, Earnings Estimates, Analyst Ratings and Key Statistics provided via Yahoo Finance, unless otherwise specified. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Jutia Group will not be liable for any errors, incompleteness or delays, or for any actions taken in reliance on the data displayed herein.

Related Articles


Comments are closed.